Ashley Lovern
Payments from drug & device makers
Across 204 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$877
- Boehringer Ingelheim$653
- GSK$379
- Lilly USA, LLC$135
- Amgen$78
- plus $256 from 8 others
What the payments were for
- Food & beverage$3,604100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 65 | $1,227 |
| Novo Nordisk | 48 | $877 |
| Boehringer Ingelheim | 35 | $653 |
| GSK | 30 | $379 |
| Lilly USA, LLC | 8 | $135 |
| Amgen | 4 | $78 |
| Xeris Pharmaceuticals, Inc. | 4 | $69 |
| Dexcom, Inc. | 3 | $56 |
| Merck | 2 | $33 |
| Mylan Specialty L.p. | 1 | $26 |
| Verona Pharma, Inc. | 1 | $19 |
| AbbVie | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
How this compares
$3,604 in reported general payments places this provider in the 85th percentile of 1,507 family providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 134 | $150,484 |
| JardianceEmpagliflozin | 148 | $115,600 |
| FarxigaDapagliflozin Propanediol | 75 | $62,261 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $58,845 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $36,362 |
| MounjaroTirzepatide | 35 | $35,928 |
| EliquisApixaban | 31 | $30,764 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $29,837 |
| LinzessLinaclotide | 30 | $21,953 |
| TradjentaLinagliptin | 17 | $15,940 |
| JanuviaSitagliptin Phosphate | 18 | $13,764 |
| XareltoRivaroxaban | 18 | $10,938 |
| EntrestoSacubitril/Valsartan | 14 | $10,734 |
| VascepaIcosapent Ethyl | 17 | $10,151 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $7,884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $877 | $150,484134 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $653 | $137,640178 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,227 | $98,623114 claims |
| GSKTrelegy Ellipta | $379 | $58,84571 claims |
| Lilly USA, LLCMounjaro | $135 | $35,92835 claims |
| AbbVieLinzess, Synthroid | $18 | $22,75043 claims |
| MerckJanuvia, Janumet | $33 | $21,64832 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,507 family providers in West Virginia.
Other family in Welch
- Ashley ComerCharleston$213K
- Dana CruseParkersburg$109K
- Sarah KnightCharleston$99K
- Star RoeBarboursville$55K
- Angela SettleCharleston$51K
- Amber DuncanCross Lanes$44K
- Jennifer FieldsHuntington$32K
- Gina LatheyScott Depot$31K
- Jodi BillerScott Depot$29K
- Misty BareboHuntington$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.